Dylann Cohn-Emery

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple myeloma.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer diagnostics with Targeted Oncology.

Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients with AML and MDS.

Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing transplant.

The California wildfires severely affected patients with cancer, requiring evacuation protocols, community support, and learning for future disaster preparedness.

In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic breast cancer.

Lisaftoclax, a BCL-2 inhibitor, demonstrated efficacy and tolerability in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma as well as amyloidosis.

Zanubrutinib demonstrated sustained progression-free survival vs bendamustine/rituximab at 5 years in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma.

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight change in findings from a retrospective trial of patients with breast cancer presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.

The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.

Firmonertinib showed efficacy and safety in patients with EGFR PACC-mutated non–small cell lung cancer.

In an interview with Peers & Perspectives in Oncology, Thomas “Greg” Knight, MD, discusses how Levine Cancer set up its Financial Toxicity Tumor Board to get the lead decision makers on the same page for patients and the importance of having this resource at all cancer centers.

In an interview, Marc Braunstein, MD, PhD, reviewed key updates in multiple myeloma for chimeric antigen receptor (CAR) T-cell and bispecific antibody therapy, and discussed planning for transition of care.

Envafolimab given subcutaneously with lenvatinib shows promise in patients with advanced endometrial cancer who were not microsatellite instability-high or mismatch repair deficient after prior lines of therapy.

The small molecule inhibitor selectively targeting HIF-2α DFF332 shows promising preliminary activity and favorable safety in patients with advanced clear cell renal carcinoma.

The combination of belumosudil plus ruxolitinib demonstrated response and tolerability in patients with steroid-refractory or steroid-dependent chronic graft-vs-host disease.

First-line lenvatinib and pembrolizumab showed similar overall survival rates and improved progression-free survival and response rates vs global standard-of-care immunotherapies among patients with advanced renal cell carcinoma.

Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.

In an interview with Peers & Perspectives in Oncology, Teresa L. Deshields, PhD, ABPP, discussed how oncologists can guide patients with cancer to mental health resources.

An exploratory analysis of Study 309/KEYNOTE-775 showed further benefit for patients and consistent safety in patients who received pembrolizumab plus lenvatinib for advanced endometrial cancer who continued lenvatinib treatment.

Researchers identified KDM6A’s role in CD38 regulation and found that an EZH2 inhibitor could potentially reduce resistance to an anti-CD38 antibody in multiple myeloma cells.

Datopotamab deruxtecan for the treatment of advanced non–small cell lung cancer is ongoing investigation in multiple clinical trials.

Uwe Platzbecker, MD, discussed findings from recent phase 3 trials and their clinical implications for daily care in patients with lower-risk myelodysplastic neoplasms.

Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.

In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed practice management strategies as a thoracic medical oncologist, including multidisciplinary care, communication between inpatient and outpatient oncology services, and advice on end-of-life care.

OMS906, a MASP-3 inhibitor, demonstrated clinical efficacy in a proof-of-concept study for patients with paroxysmal nocturnal hemoglobinuria, according to an interim analysis presented at the 2023 EHA Congress.